Abstract
Synopsis: Timolol maleate1 is a nonselective β-blocking drug used for the topical treatment of increased intraocular pressure in patients with chronic open angle glaucoma. In comparative studies it has had a somewhat greater ocular hypotensive effect than the sympathomimetic agent adrenaline (epinephrine), or lower to medium concentrations (up to 4%) of the miotic drug pilocarpine, usually lowering intraocular pressure by about 30 to 35 % (absolute pressure reduction). Timolol has been well tolerated by most patients, producing fewer subjective complaints than the comparison drugs, and objective measurements of ophthalmic status have not revealed any marked changes. Although some patients have been treated for extended periods without serious adverse effects or loss of effectiveness, further published reports in larger numbers of patients treated over several years are needed to confirm the drug’s apparent long term safety and continued efficacy. Nevertheless, on the basis of present evidence, timolol appears to represent an important advance in the topical treatment of glaucoma.
Pharmacodynamic Studies: Following topical administration, timolol significantly lowered intraocular pressure in healthy volunteers or in patients with open angle glaucoma or ocular hypertension. In studies using a range of concentrations, the maximum effect on intraocular pressure appeared to occur with a 0.5 % solution. The mechanism by which topical timolol reduces intraocular pressure is apparently primarily through a reduction in aqueous humour production. Whether or not an increase in facility of outflow of aqueous humour also occurs is unclear, divergent findings in this area having been reported.
Haemodynamic changes during timolol administration have involved only small decreases in heart rate and slight, statistically insignificant decreases in blood pressure, which were not considered to be clinically important. However, such findings were usually in patients without history of cardiac disease, bradycardia or similar disorders which might make them susceptible to β-adrenoceptor antagonists. Similarly, patients with asthma have been excluded from most studies. Thus, the safety of timolol in these patient populations needs further investigation in carefully conducted studies.
Pharmacokinetic Studies: There is no published information on the pharmacokinetic properties of timolol during ocular administration in man. Such studies are needed to determine the extent of systemic absorption. In single dose studies in rabbits, peak blood and aqueous humour levels (0.188μg/ml and 2.47μg/ml, respectively) occurred 30 minutes after ocular administration of a 0.5% solution.
Systemically absorbed timolol appears to be widely distributed in body tissues, the apparent volume of distribution being about 1.3 to 1.7L/kg after oral or intravenous doses (0.1 and 0.02mg/kg, respectively) administered to healthy volunteers. Following gastrointestinal absorption timolol was excreted primarily in the urine (73% of administered radioactivity), mainly as unidentified metabolites. The elimination half-life appeared to be about 2 to 5 hours after a 4 to 10mg oral dose in healthy subjects.
Therapeutic Trials: Timolol has been studied primarily in comparative trials with adrenaline or pilocarpine in patients with chronic open angle glaucoma. Its use in acute closed angle glaucoma has not been reported in published studies. Although a few studies have involved some patients who were treated with timolol for 2 years or longer, the number of patients who have received the drug for extended periods is relatively small.
Timolol was slightly more effective than pilocarpine (1 to 4%) in lowering intraocular pressure (about a 26 to 38 96 reduction versus 20 to 29 %) and was usually significantly more effective than adrenaline (about a 32 to 39% and a 22 to 31 % decrease with timolol and adrenaline, respectively). Although a slight reduction in the initial magnitude of the hypotensive effect of timolol occurs during the first 1 to 2 weeks of treatment, marked tachyphylaxis (as has been reported in some patients with some other topically administered β-blocking drugs, e.g. atenolol) has apparently not been a problem with timolol. Further studies in which larger numbers of patients are treated for long periods are needed before it can be definitively stated whether or not tachyphylaxis is likely to occur in some patients.
Side Effects: Timolol has been well tolerated in most patients treated to date. The incidence of subjective complaints such as burning eyes, browache, dryness of the eyes, etc. with timolol (usually about 5 to 10 % of patients) was often similar to that seen with no treatment, while adrenaline and pilocarpine produced such reactions much more frequently (usually about 20 to 30%, each).
Objective measurements of ophthalmic status during topical timolol treatment showed few changes. Importantly, no marked reduction in tear production occurred, as has been produced by systemic administration of the β-blocking agent practolol as 1 aspect of a systemic mucocutaneous disorder. However, studies reporting such data were usually only of a few months duration, and further published reports in which larger numbers of patients are treated for extended periods are needed to confirm its apparent lack of serious adverse effects.
Dosage and Administration: The recommended starting dosage of timolol is 1 drop of 0.25 % solution in the affected eye(s) twice daily. If response is inadequate the 0.5 % solution may be substituted in the same manner. When intraocular pressure is established at a satisfactory level, many patients can be adequately maintained using once daily administration.
Substitution of timolol for other glaucoma regimens should be done using both the previous regimen and timolol (0.25 %, 1 drop twice daily) on the first day and thereafter timolol alone, subsequently substituting the 0.5% solution if necessary.
Similar content being viewed by others
References
Alvan, G.; Calissendorff, B. and Seideman, P.: Availability of ocular timolol. Reported at the 7th International Congress of Pharmacology, Paris, France, July 16–21, Abstract number 2302 (1978).
Boger, W.P.; Puliafito, CA.; Steinert, R.F. and Langsten, D.B.: Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 85: 259 (1978a).
Boger, W.P.; Steinert, R.F.; Puliafito, C.A. and Pavan-Langston, D.: Clinical trial comparing timolol ophthalmic solution to pilocarpine in open-angle glaucoma. American Journal of Ophthalmology 86: 8 (1978b).
Brenkman, R.F.: Long-term hypotensive effect of atenolol 4% eyedrops. British Journal of Ophthalmology 62: 287 (1978).
Dausch, D. and Honegger, H.: Long term study on lowering effect of timolol ophthalmic solution on intraocular pressure. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Demailly, P.: Timolol, a new beta-blocking agent for the treatment of glaucoma. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Demailly, P.; Pigot, C. and Arrata, M.: Effect on diurnal pressures of timolol, administered once a day in patients with open-angle glaucoma. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Fitzgerald, J.D.: Perspectives in adrenergic beta-receptor blockade. Clinical Pharmacology and Therapeutics 10: 292 (1969).
Johnson, S.H.; Brubaker, R.F. and Trautman, J.C.: Absence of an effect of timolol on the pupil. Investigative Ophthalmology and Visual Science 17: 924 (1978).
Katz, I.M.: Efficacy and safety of long-term maintenance treatment with Timoptic ophthalmic solution in chronic open angle glaucoma. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Katz, I.M.; Hubbard, W.A.; Getson, A.J. and Gould, A.L.: Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Investigative Ophthalmology 15: 489 (1976).
Krieglstein, G.K.: Die Wirkung von Timolol-Augentropfen auf den Augeninnendruck bei Glaucoma simplex. Klinische Monatsblatter fur Augenheilkunde 172: 677 (1978).
Le Douarec, J.C.; Vareilles, P.; Plazonnet, B.; Selverstone, D.; Sears, M.L. and Stone, CA.: The effect of timolol, a β-adrenergic blocking agent, on intraocular pressure in rabbits. Pharmacologist 18: 138 (1976).
Lehner, A. and Pigot, C: Timolol in long-term therapy. Presented by Demailly, P. at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Mackie, I.A.; Seal, D.V. and Pescod, J.M.: Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. British Journal of Ophthalmology 61: 354 (1977).
Missotten, L. and Goethals, M.: Timolol reduces the standing potential of the eye. Ophthalmology Research 9: 321 (1977).
Moss, A.P.; Ritch, R.; Hargett, N.A.; Kohn, A.N. and Podos, S.M.: A comparison of the intraocular pressure effects of timolol and epinephrine in humans. American Journal of Ophthalmology, in press (1978).
Nielsen, N.V.: Timolol. Hypotensive effect, used alone and in combination for treatment of increased intraocular pressure. Acta Ophthalmologica 56: 504 (1978).
Phillips, C.I.; Gore, S.M. and Gunn, P.M.: Atenolol versus adrenaline eye drops and an evaluation of these two combined. British Journal of Ophthalmology 62: 296 (1978).
Plane, C.; Sole, P.; Ourgaud, A.-G.; Chagnon, A.; Hamard, H. and Vidal, R.: Results of a double-observer study comparing timolol to pilocarpine in open-angle glaucoma. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Radius, R.L.; Diamond, G.R.; Pollack, I.P. and Langham, M.E.: Timolol: A new drug for management of chronic simple glaucoma. Archives of Ophthalmology 96: 1003 (1978).
Ritch, R.; Hargett, N.A. and Podos, S.M. Effect of timolol maleate 1.5% on intraocular pressure. Presented at the spring meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Florida, April 25–29 (1977).
Ritch, R.; Hargett, N.A. and Podos, S.M.: The effect of 1.5% timolol maleate on intraocular pressure. Acta Ophthalmologica 56: 6 (1978).
Saari, K.M.; Airaksinen, P.J. and Jaanio, E.A.T.: Hypotensive effect of timolol on secondary glaucoma in chronic uveitis. Lancet 1: 442 (1978).
Schiffer, H.-P.: Results of a double-observer study in 50 patients comparing timolol to pilocarpine in open-angle glaucoma. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Takase, M.; Komuro, S.; Nanba, H. and Araie, M.: Effects of topical bupranolol hydrochloride on intraocular pressure. Japanese Journal of Ophthalmology 22: 142 (1978).
Tocco, D.J.; Duncan, A.E.W.; Deluna, FA.; Hucker, H.B.; Gruber, V.F. and Vandenheuvel, W.J.A.: Physiological disposition and metabolism of timolol in man and laboratory animals. Drug Metabolism and Disposition 3: 361 (1975).
Vareilles, P.; Silverstone, D.; Plazonnet, B.; Le Douarec, J.C; Sears, M.L. and Stone, C.A.: Comparison of the effects of timolol and other adrenergic agents on intraocular pressure in the rabbit. Investigative Ophthalmology and Visual Science 16: 987 (1977).
Vermeij, P.; El Sherbini-Shepers, M. and van Zweiten, P.A.: The disposition of timolol in man. Journal of Pharmacy and Pharmacology 30: 53 (1978).
Waal-Manning, H.J.: Hypertension: Which β-blocker?. Drugs 12: 412 (1976).
Wettrell, K.; Wilke, K. and Pandolfi, M.: Topical atenolol versus pilocarpine: a double-blind study of the effect on ocular tension. British Journal of Ophthalmology 62: 292 (1978).
Yablonski, M.E.; Zimmerman, T.J.; Waltman, S.R. and Becker, B.: A fluorophotometric study of the effect of topical timolol on aqueous humour dynamics. Experimental Eye Research 27: 135 (1978).
Zimmerman, T.J.: Timolol: Present research results. Presented at the 23rd International Congress of Ophthalmology, Kyoto, Japan, May 14–20 (1978).
Zimmerman, T.J. and Kaufman, H.E.: Timolol and intraocular pressure. Presented at the spring meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Florida, April 26–30 (1976).
Zimmerman, T.J. and Kaufman, H.E.: Timolol, dose response and duration of action. Archives of Ophthalmology 95: 605 (1977a).
Zimmerman, T.J. and Kaufman, H.E.: Timolol: A new drug for the treatment of glaucoma? In Leopold arid Burns (eds.), Symposium on Ocular Therapy, Volume 10, p.69 (Wiley and Sons, New York, 1977b).
Zimmerman, T.J. and Kaufman, H.E.: Timolol, a β-adrenergic blocking agent for the treatment of glaucoma. Archives of Ophthalmology 95: 601 (1977c).
Zimmerman, T.J.; Harbin, R.; Pett, M. and Kaufman, H.E.: Timolol and facility of outflow. Investigative Ophthalmology and Visual Sciences 16: 623 (1977).
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: R. Abel, Jr., Wilmington, Delaware, USA; W.P. Boger III, Department of Ophthalmology, Children’s Hospital Medical Center, Boston, Massachusetts, USA; R.F. Brenkman, Academisch Ziekenhuis-Leiden, Leiden, The Netherlands; I.H. Leopold, Department of Ophthalmology, University of California, Irvine, California, USA; C.I. Phillips, University Department of Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, Scotland; R.L. Radius, Department of Ophthalmology, Johns Hopkins Hospital, Baltimore, Maryland, USA; R. Ritch, Mount Sinai Medical Center, New York, USA; B. Schwartz, Tufts University School of Medicine, New England Medical Center Hospital, Boston, Massachusetts, USA; K. Wettrell, Department of Ophthalmology, Central Hospital, Skovde, Sweden; T.J. Zimmerman, Department of Ophthalmology, Louisiana State University Medical Center, New Orleans, USA.
Rights and permissions
About this article
Cite this article
Heel, R.C., Brogden, R.N., Speight, T.M. et al. Timolol: A Review of its Therapeutic Efficacy in the Topical Treatment of Glaucoma. Drugs 17, 38–55 (1979). https://doi.org/10.2165/00003495-197917010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197917010-00002